A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy

NCT04362761 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: ELX/TEZ/IVA
DRUG: IVA

Sponsor

Vertex Pharmaceuticals Incorporated